In vivo platelet activation is responsible for enhanced vascular endothelial growth factor levels in hypertensive patients

Clinica Chimica Acta

Volumn 388, Issue 1-2, 2008, Pages 33-37

  Ferroni, Patrizia ^a   Martini, Francesca ^a   D'Alessandro, Roberta ^a   Magnapera, Agesilao ^a   Raparelli, Valeria ^b   Scarno, Antongiulio ^b   Davì, Giovanni ^c   Basili, Stefania ^b   Guadagni, Fiorella ^a  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF CHIETI   (Italy)

Author keywords

Angiogenic factors; Aspirin; Hypertension; Platelets

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; PADGEM PROTEIN; THROMBIN ANTITHROMBIN COMPLEX; VASCULOTROPIN;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DRUG EFFECT; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; THROMBOCYTE ACTIVATION; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; ASPIRIN; FEMALE; HUMANS; HYPERTENSION; MALE; P-SELECTIN; PLATELET ACTIVATION; SOLUBILITY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 37249001872     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2007.09.026     Document Type: Article

References (28)

1. Celletti F.L., Waugh J.M., Amabile P.G., Brendolan A., Hilfiker P.R., and Dake M.D. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med 7 (2001) 425-429
2. Loomans C.J.M., Dao H.H., van Zonneveld A.J., and Rabelink T.J. Is endothelial progenitor cell dysfunction involved in altered angiogenic processes in patients with hypertension?. Curr Hypertens Rep 6 (2004) 51-54
3. Le Noble F.A.C., Staessen F.R.M., Hacking W.J.G., and Boudier A.J.S. Angiogenesis and hypertension. J Hypertens 16 (1998) 1563-1572
4. O'Brien E.R., Garvin M.R., Dev R., et al. Angiogenesis in human coronary artery plaques. Am J Pathol 145 (1994) 883-894
5. Lee S.H., Wolf P.L., Escudero R., Deutsch R., Jamieson S.W., and Thistlethwaite P.A. Early expression of angiogenesis factors in acute myocardial ischaemia and infarction. N Engl J Med 342 (2000) 626-633
6. Howell W.M., Ali S., Rose-Zerilli M.J., and Ye S. VEGF polymorphisms and severity of atherosclerosis. J Med Genet 42 (2005) 485-490
7. Blann A.D., Belgore F.M., Constans J., Conri C., and Lip G.Y. Plasma vascular endothelial growth factor and its receptor Flt-1 in patients with hyperlipidemia and atherosclerosis and the effects of fluvastatin or fenofibrate. Am J Cardiol 87 (2001) 1160-1163
8. Belgore F.M., Blann A.D., Li-Saw-Hee F.L., Beevers D.G., and Lip G.Y.H. Plasma levels of vascular endothelial growth factor and its soluble receptor (SFlt-1) in essential hypertension. Am J Cardiol 87 (2001) 805-807
9. Felmeden D.C., Spencer C.G.C., Belgore F.M., Blann A.D., Gareth Beevers D., and Lip G.Y.H. Endothelial damage and angiogenesis in hypertensive patients: relationship to cardiovascular risk factors and risk factor management. Am J Hypertens 16 (2003) 11-20
10. Nadar S.K., Blann A.D., and Lip G.Y.H. Plasma and platelet-derived vascular endothelial growth factor and angiopoietin-1 in hypertension: effects of antihypertensive therapy. J Int Med 256 (2004) 331-337
11. Patel J.V., Lim H.S., Nadar S., Tayebjee M., Hughes E.A., and Lip G.Y.H. Abnormal soluble CD40 ligand and C-reactive protein concentrations in hypertension: relationship to indices of angiogenesis. J Hypertens 24 (2006) 117-121
12. Chung N.A., Beevers D.G., and Lip G.Y.H. Effects of losartan versus hydrochlorothiazide on indices of endothelial damage/dysfunction, angiogenesis and tissue factor in essential hypertension. Blood Press 13 (2004) 183-189
13. Tsai W.C., Li Y.H., Huang Y.Y., Lin C.C., Chao T.H., and Chen J.H. Plasma vascular endothelial growth factor as a marker for early vascular damage in hypertension. Clin Sci 109 (2005) 39-43
14. Nadar S.K., Blann A., Beevers D.G., and Lip G.Y.H. Abnormal angiopoietins 1&2, angiopoietin receptor Tie-2 and vascular endothelial growth factor levels in hypertension: relationship to target organ damage [a sub-study of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)]. J Int Med 258 (2005) 336-343
15. Nadar S., and Lip G.Y. The prothrombotic state in hypertension and the effects of antihypertensive treatment. Curr Pharm Des 9 (2003) 1715-1732
16. Felmeden D.C., Spencer C.G.C., Chung N.A.Y., et al. Relation of thrombogenesis in systemic hypertension to angiogenesis and endothelial damage/dysfunction (a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial [ASCOT]). Am J Cardiol 92 (2003) 400-405
17. Bassus S., Herkert O., Kronemann N., et al. Thrombin causes vascular endothelial growth factor expression in vascular smooth muscle cells: role of reactive oxygen species. Arterioscler Thromb Vasc Biol 21 (2001) 1550-1555
18. Mohle R., Green D., Moore M.A., Nachman R.L., and Rafii S. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci U S A 94 (1997) 663-668
19. Maloney J.P., Silliman C.C., Ambruso D.R., Wang J., Tuder R.M., and Voelkel N.F. In vitro release of vascular endothelial growth factor during platelet aggregation. Am J Physiol 275 (1998) H1054-H1061
20. Verheul H.M., Hoekman K., Luykx-de Bakker S., et al. Platelet: transporter of vascular endothelial growth factor. Clin Cancer Res 3 (1997) 2187-2190
21. Martini F., Riondino S., Basili S., Bertazzoni G., and Ferroni P. In vivo platelet activation is associated to increased plasma levels of vascular endothelial growth factor. J Thromb Haemost 1 (2003) 853-854
22. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 28 (1979) 1039-1057
23. WHO memorandum. Classification of hyperlipidemias and hyperlipoproteinemias. Circulation 45 (1972) 501-508
24. Nadar S.K., Blann A., and Lip G.Y.H. Effects of aspirin on intra-platelet vascular endothelial growth factor, angiopoietin-1, and p-selectin levels in hypertensive patients. Am J Hypertens 19 (2006) 970-977
25. Pernerstorfer T., Eichler H.G., Stohlawetz P., Speiser W., and Jilma B. Effects of heparin and aspirin on circulating P-selectin, E-selectin and von Willebrand factor levels in healthy men. Atherosclerosis 155 (2001) 389-393
26. Jilma B., Blann A., Pernerstorfer T., et al. Regulation of adhesion molecules during human endotoxemia. No acute effects of aspirin. Am J Respir Crit Care Med 159 (1999) 857-863
27. Michelson A.D., Barnard M.R., Hechtman H.B., et al. In vivo tracking of platelets: circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function. Proc Natl Acad Sci U S A 93 (1996) 11877-11882
28. Jilma B., Eichler H.G., Vondrovec B., et al. Effects of desmopressin on circulating P-selectin. Br J Haematol 93 (1996) 432-436